eligard for breast cancer

Release time ：Dec-23,2024

Irinotecan may have a role in the treatment of breast cancer. This chemotherapeutic agent is primarily indicated for the treatment of malignancies such as colorectal cancer. In certain types of breast cancer, particularly those refractory to other therapeutic approaches, Irinotecan might be considered as a component of the treatment regimen.

Physicians determine the use of Irinotecan in breast cancer treatment based on the patient's condition, tumor characteristics, and overall health. Irinotecan's mechanism of action involves disrupting the synthesis and repair of cellular DNA, thereby inhibiting the proliferation and spread of cancer cells. However, due to its potent toxicity, Irinotecan can induce a range of side effects, including nausea, vomiting, diarrhea, and oral ulcers, necessitating strict adherence to medical advice and regular monitoring of the patient's blood indices and hepatic and renal functions.

For breast cancer patients receiving Irinotecan, it is crucial to vigilantly monitor their physical responses and promptly report any adverse symptoms to their healthcare provider. Patients should also adhere to the physician's instructions, complete the treatment schedule as prescribed, and avoid self-discontinuation or alteration of the dosage. Moreover, maintaining healthy lifestyle practices, such as a balanced diet, moderate physical activity, and abstaining from smoking and alcohol, can enhance treatment efficacy and overall quality of life.